Document:

Exhibit

Exhibit 10.9

AMENDMENT NO. 2 TO FORBEARANCE AGREEMENT

This Amendment No. 2 to Forbearance Agreement, dated as of June 30, 2020 (this “Agreement”) is among ENDOLOGIX, INC., a Delaware corporation (the “Borrower”), the Lenders party to this Agreement, and DEERFIELD PRIVATE DESIGN FUND IV, L.P., as agent (in such capacity, “Agent”), and amends that certain Forbearance Agreement and Amendment to Facility Agreement, dated as of May 26, 2020 (as previously amended pursuant to Amendment No. 1, dated as of June 12, 2020, the “Forbearance Agreement”), by and among the Borrower, the Agent and the Lenders party thereto.

RECITALS

WHEREAS, Borrower, the Lenders from time to time party thereto and the Agent are parties to that certain Amended and Restated Facility Agreement dated as of August 9, 2018 (as amended, supplemented, restated or otherwise modified from time to time, the “Facility Agreement”; unless otherwise defined herein, capitalized terms used herein that are not otherwise defined herein shall have the respective meanings assigned to such terms in the Facility Agreement or the Forbearance Agreement, as applicable);

WHEREAS, Borrower, the Lenders party thereto and the Agent are parties to the Forbearance Agreement, pursuant to which the Lenders party thereto and the Agent agreed to forbear from exercising certain default-related rights and remedies against Borrower and the other Loan Parties with respect to the Specified Defaults during the Forbearance Period;

WHEREAS, Borrower has advised the Lenders that it does not intend to make the interest payment in respect of the Loans due on July 1, 2020 (the “Specified Interest Payment”);

WHEREAS, pursuant to Section 5.4(a) of the Facility Agreement, the failure to make the Specified Interest Payment shall give rise to an immediate Default on such date and an Event of Default if such failure continues for three (3) Business Days after such date (the “Specified Payment Default”);

WHEREAS, the Borrower has requested that the Required Lenders and the Agent agree to amend the Forbearance Agreement as set forth therein; and

WHEREAS, the Lenders party hereto (each, a “Lender Party”) and the Agent are willing to agree to such amendment on terms and subject to conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained herein, the parties hereto agree as follows:

SECTION 1. Amendment.  Subject to the satisfaction of the conditions set forth in Section 3 hereof, the Forbearance Agreement is amended as follows:

1.1The definition of “Specified Defaults” in the Recitals to the Forbearance Agreement is hereby amended to add the Specified Payment Default (as defined above) as a Specified Default thereunder; it being understood that the amount of the Specified Interest Payment shall be capitalized and added to the outstanding principal amount of the Loans under

Exhibit 10.9

the Facility Agreement on July 1, 2020 and interest shall accrue on such capitalized amount from and after such date.

1.2Section 3(a) of the Forbearance Agreement is hereby amended by replacing the reference to “June 30, 2020” set forth therein with “July 8, 2020”.
1.3Section 7 of the Forbearance Agreement is hereby amended and restated in its entirety to read as follows:
“SECTION 7. Interest Rate. Commencing on the Default Date until the date of the Specified Payment Default (as defined in Amendment No. 2 hereto, dated as of June 30, 2020), all Obligations shall accrue interest at a rate per annum equal to the Interest Rate otherwise in effect for the Loan plus two percent (2%) per annum in accordance with Section 2.7(b)(ii) of the Facility Agreement. Commencing on the date of the Specified Payment Default and for so long as the Specified Defaults shall be continuing under the Facility Agreement, all Obligations shall accrue interest at a rate per annum equal to the Interest Rate otherwise in effect for the Loan plus 12% per annum in accordance with Section 2.7(b)(i) and 2.7(b)(ii) of the Facility Agreement.”

SECTION 2.   No Other Amendments or Waivers.

The Forbearance Agreement (as amended hereby), and the terms and provisions hereof and thereof, constitute the entire agreement among the parties hereto pertaining to the subject matter hereof and supersedes any and all prior or contemporaneous amendments relating to the subject matter hereof. Except for the forbearance expressly set forth in Section 3 of the Forbearance Agreement (as amended hereby), the Facility Agreement shall remain unchanged and in full force and effect. Except as expressly set forth in Section 3 of the Forbearance Agreement (as amended hereby), the execution, delivery, and performance of this Agreement shall not operate as a waiver of or as an amendment of, any right, power, or remedy of Agent or the Lenders party thereto under the Facility Agreement or any of the other Loan Documents as in effect prior to the date hereof, nor constitute a waiver of any provision of the Facility Agreement or any of the other Loan Documents. The agreements set forth within the Forbearance Agreement (as amended hereby) are limited to the specifics hereof, shall not apply with respect to any facts or occurrences other than those on which the same are based, shall not excuse future non-compliance under the Facility Agreement or other Loan Documents, and shall not operate as a consent to any further or other matter, under the Loan Documents.

SECTION 3. Conditions Precedent. The effectiveness of this Agreement is subject to the satisfaction of the following conditions precedent on the date hereof:

3.1Execution  of  Agreement.    Each Loan Party, Agent and the Required Lenders shall have duly executed and delivered this Agreement.
3.2Accuracy  of  Representations  and  Warranties.    All representations and warranties contained in Section 4 hereof shall be true and correct in all respects.
3.3ABL Forbearance Amendment. An amendment to the ABL Forbearance Agreement shall be effective and on terms acceptable to the Lender Parties.
SECTION 4. Representations and Warranties. To induce the Lenders and the Agent to execute and deliver this Agreement, on behalf of itself and the other Loan Parties, Borrower hereby represents and warrants to the Lenders and the Agent that:

Exhibit 10.9

4.1as of the date hereof, and after giving effect to this Agreement, the representations and warranties set forth in Section 3.1 of the Facility Agreement and in the other Loan Documents shall be true and correct in all material respects (without duplication of any materiality qualifier contained therein) on and as of the date hereof with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (without duplication of any materiality qualifier contained therein) as of such earlier date;
4.2immediately before and after giving effect to this Agreement, no Default or Event of Default (other than any Specified Default) has occurred and is continuing;
4.3each of Borrower and each other Loan Party has taken all necessary action to authorize the execution, delivery and performance of this Agreement, this Agreement has been duly executed and delivered by each of Borrower and each other Loan Party and this Agreement is the legal, valid and binding obligation of each of Borrower and each other Loan Party, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general principles of law; and
4.4other than the ABL Forbearance Agreement, as of the date hereof, no Third Party Forbearance Agreements exist.
SECTION 5. Reaffirmation and Release. Each Loan Party, by its signature below, hereby agrees that:

5.1(i) after giving effect to this Agreement,  the  Facility  Agreement, Security Agreement and each other Loan Document shall continue to be in full force and effect and (ii) affirms and confirms all of its obligations and liabilities under the Facility Agreement, the Security Agreement and each other Loan Document, in each  case  after  giving  effect  to  this Agreement, including its guarantee of the Obligations and the pledge of and/or grant of a security interest in its assets as Collateral pursuant to the Agreement to  secure  such  Obligations, all as provided in the Security Agreement as originally executed, and acknowledges and agrees that such obligations, liabilities, guarantee, pledge and grant continue in full force and effect in respect of, and to secure, the Obligations  under  the  Facility  Agreement  and  the  other Loan Documents, in each case after giving effect to this Agreement; and
5.2after giving effect to this Agreement, each Lien granted by it to the Agent for the benefit of the Secured Parties under each of the Loan Documents to which it is a party shall (i) continue in full force and effect during the term of the Facility Agreement and (ii) continue to secure the Obligations, in each case on and subject to the terms and conditions set forth in the Facility Agreement and the other Loan Documents.
		
	5.3
	Release.

(a)In consideration of this Agreement and agreements of the Agent and Lender Parties contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Borrower and the other Loan Parties (collectively, the “Releasing Parties”), each on behalf of itself and its successors, assigns, and other legal representatives hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent, the Lender Parties, solely in their capacities as Lenders, and their respective present and former shareholders, affiliates, 

Exhibit 10.9

subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives, in each case solely in their capacities relative to the Lender Parties and not in any other capacity such party may have relative to the Releasing Parties (Agent, each Lender Party, and all such other Persons being hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, the Loan Parties or any of their respective successors, assigns or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Agreement, for or on account of, or in relation to, or in any way in connection with the Facility Agreement or any of the other Loan Documents or transactions thereunder (any of the foregoing, a “Claim” and collectively, the “Claims”). Each Releasing Party expressly acknowledges and agrees, with respect to the Claims, that it waives, to the fullest extent permitted by applicable law, any and all provisions, rights, and benefits conferred by any applicable U.S. federal or state law, or any principle of U.S. common law, that would otherwise limit a release or discharge of any unknown Claims pursuant to this Section 5.3. Furthermore, each of the Releasing Parties hereby absolutely, unconditionally and irrevocably covenants and agrees with and in favor of each Releasee that it will not sue (at law, in equity, in any regulatory proceeding or otherwise) any Releasee on the basis of any Claim released and/or discharged by the Releasing Parties pursuant to this Section 5.3. The foregoing release, covenant  and waivers of this Section 5.3 shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment or prepayment of any of the Loans, or the termination of the Facility Agreement, this Agreement, any other Loan Document or any provision hereof or thereof.
(b)Each Releasing Party understands, acknowledges and agrees that its release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.
(c)Each Releasing Party agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.
SECTION 6. Miscellaneous.

6.1Captions. Section captions used in this Agreement are for convenience only, and shall not affect the construction of this Agreement.
6.2Governing Law. UNLESS EXPRESSLY PROVIDED IN ANY LOAN DOCUMENT, THIS AGREEMENT AND ALL CLAIMS SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ANY CONFLICT OF LAW PRINCIPLES EXCEPT FEDERAL LAWS RELATING TO NATIONAL BANKS.
6.3Severability. Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be valid under Applicable Law. If any provision is found to be invalid under Applicable Law, it shall be ineffective only to the extent of such invalidity and the 

Exhibit 10.9

remaining provisions of this Agreement shall remain in full force and effect.

6.4Successors and Assigns. This Agreement shall be binding upon the parties hereto and their respective successors and assigns, and shall inure to the sole benefit of the parties and their respective successors and assigns.

6.5References. Any reference to the Facility Agreement contained in any notice, request, certificate, or other document executed concurrently with or after the execution and delivery of this Agreement shall be deemed to include this Agreement unless the context shall otherwise require.
6.6Loan Document. This Agreement shall be deemed to be and shall constitute a Loan Document.
6.7Continued Effectiveness. Notwithstanding anything contained herein, the terms of this Agreement are not intended to and do not serve to effect a novation as to the Facility Agreement. The Facility Agreement and each of the Loan Documents remain in full force and effect.
6.8Entire Agreement. This Agreement constitutes the entire agreement, and supersedes all prior understandings and agreements, among the parties relating to the subject matter thereof.
6.9Counterparts; Execution. This Agreement may be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement shall become effective when Agent has received counterparts bearing the signatures of all parties hereto. Delivery of a signature page of this Agreement by telecopy or other electronic means shall be effective as delivery of a manually executed counterpart of such agreement. Any signature, contract formation or record-keeping through electronic means shall have the same legal validity and enforceability as manual or paper-based methods, to the fullest extent permitted by Applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any similar state law based on the Uniform Electronic Transactions Act.

[Remainder of Page Intentionally Left Blank]

Exhibit 10.9

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

 BORROWER:

ENDOLOGIX, INC.

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

 

[Signature Page to Amendment to Term Loan Forbearance Agreement]

Exhibit 10.9

GUARANTORS:

CVS/DMS ACQUISITION CORP.

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

NELLIX, INC.

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

TRIVASCULAR TECHNOLOGIES, INC.

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

TRIVASCULAR, INC.

By:  /s/ John Onopchenko    
Name:  John Onopchenko
Title:    CEO

ENDOLOGIX CANADA, LLC

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

TRIVASCULAR SALES LLC

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

RMS/ENDOLOGIX SIDEWAYS MERGER CORP.

By:  /s/ John Onopchenko    
Name: John Onopchenko
Title: CEO

[Signature Page to Amendment to Term Loan Forbearance Agreement]

Exhibit 10.9

AGENT AND LENDERS:

DEERFIELD PRIVATE DESIGN FUND
IV, LP., as Agent and Lender

By: Deerfield Mgmt IV, L.P., General Partner

By: J.E. Flynn Capital IV, LLC, General
Partner
        
          By: /s/ David Clark                                            
    Name: David Clark
                                                                                        Title: Authorized Signatory

DEERFIELD PARTNERS, L.P., as Lender

By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General
       Partner

                                           By: /s/ David Clark                                          
    Name: David Clark
                                                                                        Title: Authorized Signatory

DEERFIELD PRIVATE DESIGN FUND
III, L.P., as Lender

By: Deerfield Mgmt III, L.P., General Partner

By: J.E. Flynn Capital III, LLC, General
       Partner

                                            By: /s/ David Clark                                           
    Name: David Clark
                                                                                        Title: Authorized Signatory

[Signature Page to Amendment to Term Loan Forbearance Agreement]clsd-ex101_237.htm

Exhibit 10.1

FIRST AMENDMENT TO LICENSE AGREEMENT

This First Amendment to License Agreement (the “Amendment”), effective as of April 27, 2020 (the “Amendment Effective Date”) by and between Bausch Health Ireland Limited (“Bausch Health”) and Clearside Biomedical, Inc. (“Clearside”), amends that certain License Agreement, dated October 22, 2019, by and between Bausch Health and Clearside (the “Agreement”).  Each of Bausch and Clearside shall be referred to herein individually as a “Party” and collectively as the “Parties.”

NOW, THEREFORE, in consideration of the mutual promises set forth herein, the Parties hereby agree as follows:

Article I.AGREEMENT AMENDMENT

1.Section 1.98 of the Agreement is hereby amended by deleting in its entirety and replacing it with the following:

“Territory” means, collectively, (a) the Original Territory and (b) any Additional Region for which Bausch Health has exercised its Option pursuant to Section 2.8(a) and which has not been terminated pursuant to Section 2.8(b) or (c). 

2. Article 1 of the Agreement is hereby amended by adding the following new definitions to that section:

 “European Union” means the economic, scientific and political organization of European member states, as its membership may be altered from time to time, and any successor thereto; provided, that for the purposes of this Agreement, the European Union shall always include the United Kingdom. 

“Major Market” means [***].

 “Original Territory” means Canada and the U.S. 

3.The following shall be added to the Agreement as Section 2.8:

2.8Bausch Health’s Option.  

(a)Clearside hereby grants to Bausch Health an exclusive option to add one (1) or more of the following regions to the definition of “Territory” under this Agreement, solely in connection with Bausch Health’s rights or obligations with respect to XIPERE Product(s): (i) European Union, (ii) Australia and New Zealand and (iii) South America and Mexico (each, an “Additional Region”; collectively, the “Additional Regions”; such option, the “Option”).  The Option shall commence on the Amendment Effective Date and continue until the earlier of (i) the date of FDA Regulatory Approval of Product and (ii) August 31, 2021  (such period, the “Option Term”; the end date, the “Option End Date”). Bausch Health may exercise the Option with respect to each Additional Region by delivering a written exercise notice to Clearside. With respect to 

1

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.

 

 

each Additional Region, if Bausch Health fails to exercise its Option before the Option End Date, then Clearside shall have the right to exploit the XIPERE Products in such Additional Regions, either on its own or in collaboration with a Third Party, with no further obligations owed to Bausch Health.  In the event that Bausch Health timely exercises its Option for a given Additional Region, such Additional Region shall be automatically added to the Territory as of the date of the exercise of such Option and the terms of the Agreement (including the license grant in Section 2.1) shall apply to such Additional Region as part of the Territory (except to the extent expressly stated in Section 7 below). In addition, in the event that Bausch Health timely exercises its Option for a given Additional Region, the Parties shall add applicable Licensed Patents and Licensed Marks to Exhibit 1.64 and Exhibit 1.63, respectively, as well as discuss in good faith the disclosure and transfer of any Licensed Know-How and Regulatory Submissions (including any Regulatory Approvals) relevant to the Additional Regions (which disclosure and/or transfer shall occur within a commercially reasonable time after Bausch Health’s exercise of the Option). In addition, in the event that Bausch Health timely exercises its Option for a given Additional Region, the Parties shall discuss and negotiate, in good faith and acting reasonably, any necessary or desired changes to the Safety Agreement resulting from the addition of any Additional Regions. For the avoidance of doubt, Clearside does not, and nothing herein shall be deemed to, grant Bausch Health any license or right to Develop, Manufacture, have Manufactured, Commercialize or otherwise use or exploit Other Products in any Additional Region. 

(b) For each Additional Region for which Bausch Health exercises its Option, Bausch Health shall use Commercially Reasonable Efforts to Develop and to obtain Regulatory Approval for at least [***] in at least [***] in such Additional Region, [***].  If [***], then, as Clearside’s sole remedy [***], all rights granted to Bausch Health with respect to such Additional Region shall automatically terminate and shall promptly revert to Clearside on a fully paid-up and royalty-free basis, and the effects of termination set forth in Section 13.3 shall thereafter apply with respect to such Additional Region.  

(c) If [***], then all rights granted to Bausch Health with respect to such Additional Region shall automatically terminate and shall revert to Clearside on a fully paid-up and royalty-free basis, and the effects of termination set forth in Section 13.3 shall thereafter apply with respect to such Additional Region.

(d) [***].

(e) During the Option Term, on reasonable request from Bausch Health but no more than once during the Option Term, representatives of Clearside and Bausch Health shall meet with each other in-person, by video or telephonically, for the purposes of Clearside providing Bausch Health with an update on the current status of the XIPERE Product in each of the Additional Regions, answering any reasonable questions of Bausch Health respecting the XIPERE Product in the Additional Regions and providing Bausch Health with any reasonable documentation or 

2

 

 

information reasonably requested by Bausch Health, excluding, for clarity, the data and information contained in the Device Master File.

 

4.Section 8.1(b) of the Agreement is hereby amended by revising it as follows: 

(a) deleting the following milestones in their entirety, together with their associated payments: [***]; and 

(b) adding the following milestones to the end of the milestone table: (i) [***]; and (ii) [***]. For clarity, the milestone payments set forth in subsections (i) and (ii) of this subsection (b) shall be payable only in the event Bausch Health exercises its Option with respect to the European Union.

5.Section 8.2(a) shall be deleted in its entirety and replaced with the following:

(a)Earned Royalties. During the applicable Royalty Term, Bausch Health shall make quarterly non-refundable, non-creditable (provided that specified costs incurred by Bausch Health pursuant to Section 4.1(a), Section 4.3 or Section 8.2(e) may be credited against such payments, as described in Section 4.1(a), Section 4.3 or Section 8.2(e), as the case may be) royalty payments to Clearside on Net Sales of all Products sold in the Original Territory or the Additional Regions, as applicable, during the applicable Calendar Quarter, as calculated by multiplying the applicable royalty rate set forth below by the corresponding amount of Net Sales of all such Products sold in the Original Territory or the Additional Regions, as applicable, for such Calendar Quarter. Notwithstanding the foregoing, no such royalties shall be due or payable by Bausch Health on the first Forty-Five Million Dollars ($45,000,000) of aggregate Net Sales of all Products in the Original Territory, calculated on a cumulative (and not annual) basis. Once cumulative Net Sales on all Products in the Original Territory achieves Forty-Five Million Dollars ($45,000,000), royalties will then be calculated as follows with respect to Net Sales of Products in the Original Territory: (i) on Net Sales of each XIPERE Product in the Original Territory, and the applicable royalty rates below for XIPERE Products will be applied, and (ii) on Net Sales of each Other Product in the Original Territory, and the royalty rate below for Other Products will be applied. 

		
	
Annual  Net Sales in the Territory
	
Royalty Rate

	
Annual Net Sales of XIPERE Products in the Original Territory 

	
Portion of annual Net Sales up to and including [***]
	
[***]%

	
Portion of annual Net Sales above [***]
	
[***]%

	
Annual Net Sales of Other Products in the Original Territory
	
[***]%

	
Annual Net Sales of XIPERE Products in the Additional Regions

	
Portion of annual Net Sales up to and including [***]
	
[***]%

3

 

 

		
	
Portion of annual Net Sales above [***]
	
[***]%

Notwithstanding the above, for the Calendar Year in which the cumulative Net Sales on all Products in the Original Territory first achieves Forty-Five Million Dollars ($45,000,000), the calculation of annual Net Sales for the purposes of determining the royalty rate on XIPERE Products for such Calendar Year shall be calculated commencing with the first dollar after the achievement of such cumulative Net Sales of Forty-Five Million Dollars ($45,000,000). In addition, for XIPERE Products, each royalty rate set forth in the table immediately above shall only be applied to the annual Net Sales of the XIPERE Product within the applicable royalty range. For example, royalties due to Clearside for annual Net Sales of the XIPERE Product in the Original Territory of [***] would be calculated as follows:

			
	
Royalty  =
	
[***] =
	
[***]

	
 
	
[***] =
	
[***]

	
 
	
 
	
[***]

6.Section 13.2(a) of the Agreement shall be deleted in its entirety and replaced with the following:

	
 
	
13.2
	
Termination for Failure to Receive Approval. Bausch Health may terminate the Agreement immediately upon written notice to Clearside if the FDA has not approved the XIPERE NDA by August 31, 2021; provided that, such termination right shall expire on the earlier of (i) the approval of the XIPERE NDA or (ii) [***]. 

7.Section 15.8 of the Agreement is hereby amended by adding the following to the end of that section: 

Notwithstanding anything to the contrary in this Agreement, all references to “Territory” shall mean the “Original Territory” in the following provisions: [***].  

Article II.MISCELLANEOUS

1.Capitalized terms not defined herein shall have the same meanings as set forth in the Agreement. 

2.Except as set forth herein, all other terms and conditions of the Agreement shall remain in full force and effect. 

3.This Amendment may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures were upon the same instrument. This Amendment shall become binding when each Party shall have received a counterpart of such agreement signed by the other Parties.

 

[signature page follows]

4

 

 

THIS FIRST AMENDMENT TO LICENSE AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the Amendment Effective Date.

	
CLEARSIDE BIOMEDICAL, INC. 
	
BAUSCH HEALTH IRELAND LIMITED

 

Signature:/s/ George LasezkaySignature: /s/ Graham Jackson

Name: George LasezkayName:Graham Jackson

Title: CEOTitle: Director

Date: April 27, 2020Date: April 27, 2020

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]